Suppression of the TRIF-dependent signaling pathway of TLRs by epoxomicin.
Arch Pharm (Weinheim). 2021 Sep;354(9):e2100130. doi: 10.1002/ardp.202100130. Epub 2021 May 31.
Arch Pharm (Weinheim). 2021.
PMID: 34060134